Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.100
+0.030 (2.80%)
At close: May 22, 2026, 4:00 PM EDT
1.110
+0.010 (0.91%)
After-hours: May 22, 2026, 7:54 PM EDT

Quince Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
18187824523380
Market Cap Growth
-60.55%126.88%82.36%95.90%-93.93%-53.75%
Enterprise Value
0.06169.2656.21-16.19-67.15273.16
Last Close Price
1.1033.5018.7010.506.37126.20
PB Ratio
0.97-5.232.730.530.233.20
P/TBV Ratio
0.44-4.702.680.460.213.16
EV/EBITDA Ratio
---0.471.30-
EV/EBIT Ratio
---0.471.29-
EV/FCF Ratio
---0.881.52-
Debt / Equity Ratio
0.02-0.010.490.1600.00
Net Debt / Equity Ratio
-1.14-0.02-0.86-0.72-0.90-0.90
Net Debt / EBITDA Ratio
0.31-0.010.461.791.741.18
Net Debt / FCF Ratio
0.45-0.010.813.322.041.69
Quick Ratio
2.070.415.607.8429.387.51
Current Ratio
2.920.536.058.0930.557.85
Return on Equity (ROE)
373.03%2785.60%-98.33%-34.23%-47.66%-61.85%
Return on Assets (ROA)
-90.28%-58.06%-40.64%-25.31%-43.63%-55.98%
Return on Invested Capital (ROIC)
-173.18%-93.35%-74.61%-70.19%-452.51%-355.20%
Return on Capital Employed (ROCE)
-169.62%-73.74%-43.15%-26.72%-47.32%-61.97%
Buyback Yield / Dilution
-42.34%-15.80%-16.18%-11.17%-12.71%-1.86%
Total Shareholder Return
-42.34%-15.80%-16.18%-11.17%-12.71%-1.86%
Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q